Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H13NO2 |
Molecular Weight | 167.205 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC[C@H](O)C1=CC(O)=CC=C1
InChI
InChIKey=SONNWYBIRXJNDC-VIFPVBQESA-N
InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
DescriptionSources: http://www.drugbank.ca/drugs/DB00388Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and
https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html
Sources: http://www.drugbank.ca/drugs/DB00388
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and
https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html
Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities. Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22391890
Curator's Comment: Phenylephrine does not cross the blood–brain barrier
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00388 |
55.0 nM [EC50] | ||
Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25813897 |
5.9 nM [EC50] | ||
Target ID: CHEMBL326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8831777 |
154.88 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VAZCULEP Approved UseVAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important
hypotension resulting primarily from vasodilation in the setting of anesthesia. Launch Date-5.05007997E11 |
|||
Diagnostic | Phenylephrine Hydrochloride Ophthalmic Solution Approved UseIndicated to dilate the pupil Launch Date-9.7839363E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2959 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4492 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1354 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2346 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3900 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
955.8 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.93 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.64 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.89 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYLEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: |
Disc. AE: Ischemic colitis... AEs leading to discontinuation/dose reduction: Ischemic colitis (acute) Sources: |
40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Disc. AE: Chest pain, Jaw pain... Other AEs: Nervous system disorders, Headache... AEs leading to discontinuation/dose reduction: Chest pain (1 patient) Other AEs:Jaw pain (1 patient) Nervous system disorders (3.6%) Sources: Headache (2.7%) Gastrointestinal disorders (8%) Dry mouth (2.7%) Nausea (3.6%) |
10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
Other AEs: Eye pain, Blurred vision... Other AEs: Eye pain Sources: Blurred vision Photophobia Allergic conjunctivitis |
250 ug single, intravenous Recommended Dose: 250 ug Route: intravenous Route: single Dose: 250 ug Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ischemic colitis | acute Disc. AE |
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: |
Chest pain | 1 patient Disc. AE |
40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Jaw pain | 1 patient Disc. AE |
40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Dry mouth | 2.7% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Headache | 2.7% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Nausea | 3.6% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Nervous system disorders | 3.6% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Gastrointestinal disorders | 8% | 40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: |
unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: |
Allergic conjunctivitis | 10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
|
Blurred vision | 10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
|
Eye pain | 10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
|
Photophobia | 10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: |
healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16510159/ Page: 10.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Altered baroreflex control of heart rate in bradykinin B2-receptor knockout mice. | 1999 Dec |
|
Involvement of ATP-sensitive potassium channels in a model of a delayed vascular hyporeactivity induced by lipopolysaccharide in rats. | 1999 Jul |
|
Microphysiometric analysis of human alpha1a-adrenoceptor expressed in Chinese hamster ovary cells. | 1999 Jun |
|
Investigation of the effects of some alkaloidal alpha1-adrenoceptor antagonists on human hyperplastic prostate. | 1999 Jun 25 |
|
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors. | 2000 Apr |
|
Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. | 2000 Apr 1 |
|
Alpha(1) adrenergic agonist induction of p21(waf1/cip1) mRNA stability in transfected HepG2 cells correlates with the increased binding of an AU-rich element binding factor. | 2000 Apr 21 |
|
Gene transfer of endothelial nitric oxide isoform decreases rat hindlimb vascular resistance in vivo. | 2000 Aug 10 |
|
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. | 2000 Feb 15 |
|
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. | 2000 Feb 18 |
|
Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. | 2000 Jan |
|
Bupivacaine inhibits baroreflex control of heart rate in conscious rats. | 2000 Jan |
|
Minidose bupivacaine-fentanyl spinal anesthesia for surgical repair of hip fracture in the aged. | 2000 Jan |
|
Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity. | 2000 Jan-Feb |
|
Fine structure and plasticity of barosensitive neurons in the nucleus of solitary tract. | 2000 Jul 3 |
|
Presence of NMDA receptor subunits in the male lower urogenital tract. | 2000 Jul-Aug |
|
The Rho effector, PKN, regulates ANF gene transcription in cardiomyocytes through a serum response element. | 2000 Jun |
|
Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice. | 2000 Mar |
|
Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. | 2000 May 5 |
|
The effect of phenylephrine on pain and flare intensity in eyes with uveitis. | 2000 Oct |
|
Intracarotid infusion of the nitric oxide synthase inhibitor, L-NMMA, modestly decreases cerebral blood flow in human subjects. | 2000 Sep |
|
Heparin-mediated hypotension associated with cardiac surgery. | 2000 Sep |
|
Effects of salt intake and angiotensin II on vascular reactivity to endothelin-1. | 2001 Feb |
|
Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility. | 2001 Feb |
|
Nitric oxide-mediated arteriolar dilation after endothelial deformation. | 2001 Feb |
|
Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control. | 2001 Feb |
|
Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system. | 2001 Feb |
|
Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin. | 2001 Feb 1 |
|
Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. | 2001 Feb 13 |
|
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. | 2001 Jan |
|
Exercise attenuates alpha-adrenergic-receptor responsiveness in skeletal muscle vasculature. | 2001 Jan |
|
Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude. | 2001 Jan |
|
Should the angiotensin II antagonists be discontinued before surgery? | 2001 Jan |
|
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. | 2001 Jan |
|
Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats. | 2001 Jan |
|
Increased alpha(1)- and alpha(2)-adrenoceptor-mediated contractile responses of human skeletal muscle resistance arteries in chronic limb ischemia. | 2001 Jan |
|
Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. | 2001 Jan |
|
Assessment of baroreflex sensitivity in patients with preserved and impaired left ventricular function by means of the Valsalva manoeuvre and the phenylephrine test. | 2001 Jan |
|
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using. | 2001 Jan 12 |
|
Relaxation of rat aorta by adenosine in diabetes with and without hypertension: role of endothelium. | 2001 Jan 19 |
|
Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. | 2001 Jan 5 |
|
Insulin-induced relaxation of rat mesenteric artery is mediated by Ca(2+)-activated K(+) channels. | 2001 Jan 5 |
|
Phosphatidylinositol 4,5-bisphosphate is acting as a signal molecule in alpha(1)-adrenergic pathway via the modulation of acetylcholine-activated K(+) channels in mouse atrial myocytes. | 2001 Jan 5 |
|
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors. | 2001 Mar |
|
Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel. | 2001 Mar |
|
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. | 2001 Mar |
|
Endogenous estrogen mediates vascular reactivity and distensibility in pregnant rat mesenteric arteries. | 2001 Mar |
|
Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence. | 2001 Mar |
|
EDHF contributes to strain-related differences in pulmonary arterial relaxation in rats. | 2001 Mar |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Also used as Ophthalmic Solution or oral tablets
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
https://www.drugs.com/dosage/chlorpheniramine-phenylephrine.html
VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected
intravenously either as a bolus or in a dilute solution as a continuous infusion.
Dilute before administration.
Dosing for treatment of hypotension during anesthesia
Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as
needed, not to exceed 200 mcg.
Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to
exceed 200 mcg/min.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26406609
The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
773
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-VATC |
QR01BA03
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-VATC |
QS01FB01
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-VATC |
QR01AA04
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-VATC |
QC01CA06
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
R01BA03
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
R01AB01
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
R01BA53
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-VATC |
QS01GA55
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
C01CA06
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
S01BB01
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-VATC |
QS01GA05
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-VATC |
QR01AB01
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
S01FB51
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
S01FB01
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
FDA ORPHAN DRUG |
147201
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-VATC |
QR01BA53
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
S01GA55
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
NDF-RT |
N0000186105
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
R01AA04
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
WHO-ATC |
S01GA05
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
||
|
FDA ORPHAN DRUG |
359011
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C62067
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
59-42-7
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
8163
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
D010656
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
CHEMBL1215
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
325517
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
ALTERNATIVE | |||
|
1WS297W6MV
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
8093
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
DTXSID9023465
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
485
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
SUB09788MIG
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
3383
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
DB00388
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
Phenylephrine
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
6041
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
200-424-8
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
2146
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
N0000009917
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | Adrenergic alpha1-Agonists [MoA] | ||
|
1WS297W6MV
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
m8668
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000088260
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
PHENYLEPHRINE
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY | |||
|
4174
Created by
admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)